Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Base editing rescues seizures and sudden death in a SCN8A mutation-associated developmental epileptic encephalopathy model
Caeley M. Reever, Alexis R. Boscia, Tyler C.J. Deutsch, Mansi P. Patel, Raquel M. Miralles, Shrinidhi Kittur, Erik J. Fleischel, Atum M.L. Buo, Matthew S. Yorek, Miriam H. Meisler, Charles R. Farber, Manoj K. Patel
Caeley M. Reever, Alexis R. Boscia, Tyler C.J. Deutsch, Mansi P. Patel, Raquel M. Miralles, Shrinidhi Kittur, Erik J. Fleischel, Atum M.L. Buo, Matthew S. Yorek, Miriam H. Meisler, Charles R. Farber, Manoj K. Patel
View: Text | PDF
Research Article Genetics Neuroscience

Base editing rescues seizures and sudden death in a SCN8A mutation-associated developmental epileptic encephalopathy model

  • Text
  • PDF
Abstract

SCN8A encodes the voltage-gated sodium channel Nav1.6, which plays a key role in facilitating neuronal excitability. Mutations in SCN8A, particularly gain-of-function variants, cause SCN8A developmental and epileptic encephalopathy (DEE), a severe epilepsy syndrome characterized by seizures, cognitive dysfunction, movement disorders, and sudden unexpected death in epilepsy (SUDEP). The recurrent SCN8A variant R1872W impairs channel inactivation, causing neuronal hyperexcitability and seizures. Current treatments, including antiseizure medications, are often ineffective for patients with SCN8A DEE, highlighting the need for targeted therapies. We employed base editing to correct the R1872W SCN8A variant. An adenine base editor and guide RNA (SCN8A-ABE) were packaged within dual PhP.eB-adeno-associated viruses (AAVs) and administered to R1872W mice at P2. SCN8A-ABE significantly increased survival of mice expressing R1872W and either reduced seizure incidence and severity or eliminated seizure occurrence. Electrophysiological recordings revealed a rescue of seizure-associated neuronal hyperexcitability and suppression of the pathogenic persistent sodium current (INaP) in treated mice. Comorbidities, including diminished mobility and anxiety-like behaviors, were improved by SCN8A-ABE. These effects were achieved by a 32% absolute reduction in mutant transcripts, accompanied by conversion to SCN8A WT transcripts. Our findings demonstrate base editing as an effective targeted therapeutic approach for SCN8A DEEs by addressing the underlying genetic cause.

Authors

Caeley M. Reever, Alexis R. Boscia, Tyler C.J. Deutsch, Mansi P. Patel, Raquel M. Miralles, Shrinidhi Kittur, Erik J. Fleischel, Atum M.L. Buo, Matthew S. Yorek, Miriam H. Meisler, Charles R. Farber, Manoj K. Patel

×

Figure 4

SCN8A-ABE attenuates neuronal hyperexcitability and reduces the pathological persistent sodium current (INaP).

Options: View larger image (or click on image) Download as PowerPoint

SCN8A-ABE attenuates neuronal hyperexcitability and reduces the patholo...
(A) GFP expression in 30 μm sectioned brain tissue (P25) from Scn8aW/+-EMX1 mouse injected with the SCN8A-ABE and AAV-GFP viruses. Scale bar: 0.5 mm. (B) GFP labeling of cortical layers (LI-LVI) in Scn8aW/+-EMX1 mouse injected with SCN8A-ABE and AAV-GFP virus (Scale bar 0.2 mm). Inset (Right) shows GFP labeling of cortical layer LIV/LV pyramidal neurons. Scale bar: 0.01 mm. (C) Example traces of action potential firing from Scn8aW/+-EMX1 sham control (green), Scn8aW/+-control (black), and Scn8aW/+-EMX1 SCN8A-ABE–treated (purple) cortical layer LIV/LV pyramidal neurons at current injection steps of 200 pA, 400 pA, or 600 pA (P17-P25). (D) Average number of action potentials elicited relative to current injection magnitude. At current injections greater than 240 pA, Scn8aW/+-EMX1 Sham neurons (n = 25, 4 mice) exhibit increased firing frequencies when compared with Scn8aW/+-control (n = 21, 4 mice). This hyperexcitability is significantly attenuated in Scn8aW/+-EMX1 SCN8A-ABE–treated neurons (n = 33 cells, 7 mice; ***P < 0.001, ****P < 0.0001; nested 1-way ANOVA with Dunns’s multiple comparisons test). (E) Example traces of steady state INaP evoked by slow voltage ramps in pyramidal neurons from Scn8aW/+-EMX1 sham (green), Scn8aW/+-control (black), and Scn8aW/+-EMX1 SCN8A-ABE–treated mice (purple). Traces in gray show slow voltage ramp in the presence of 500 nM TTX. (F) Elevated maximum INaP in Scn8aW/+-EMX1 sham control neurons (n = 24, 8 mice) is rescued by SCN8A-ABE treatment in Scn8aW/+-EMX1 neurons (n = 18, 8 mice) to amplitudes recorded in Scn8aW/+-control neurons (n = 17, 6 mice; *P < 0.05, ****P < 0.0001; Kruskal-Wallis with Dunn’s multiple comparisons). No significant difference observed between Scn8aW/+ EMX1 SCN8A-ABE–treated and Scn8aW/+-control groups. Data points represent individual recordings, bars represent mean ± SEM.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts